GNBT - Buy One Share Of Biotech’s New Fast Rising Star And Get One Free
August 9, 2019 -- InvestorsHub NewsWire -- via BioResearchAlert
About: Generex Biotechnology Corporation (GNBT)
Share price in strong uptrend for past 10 months.
1 Share dividend for each share owned will only be paid the day after Generex Biotechnology is up-listed to Nasdaq.
Nasdaq Up-listing expected in 30 to 60 days.
Stock dividend will only be paid to float shareholders and not to management or insider shareholders.
Management has completely restructured company into powerful healthcare growth engine.
Generex A37 Immunotherapy Vaccine demonstrates high efficacy with low adverse side effects against breast cancer and believes it’s also effective against many common cancers and diseases.
Combination Phase II trial with MRK Keytruda and GNBT A37 for Breast Cancer enrolling 2019.
Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
Proprietary buccal oral insulin delivery for $27 billion insulin market.
Aggressive acquisition strategy of diagnostics, therapeutics, orthopedic surgical implants and patient care in play with recent closes and signed LOI’s.
Summary
Shares of Generex Biotechnology Corporation (OTC: OTCQB:GNBT) have been rising and continue in a strong uptrend for several reasons. Unlike many biotech companies that are developing just one technology and have only one drug or very few drugs in their pipeline, Generex is successfully executing an aggressive acquisition strategy to own a broad spectrum of diagnostic products, therapeutic products, orthopedic implants, surgical kits, biologic products, and care delivery solutions through their MSO.
Joseph Moscoto, CEO, has thoroughly restructured Generex Biotechnology and has assembled an experienced and effective management team that has successfully architected several acquisitions that have either been closed, or that are under LOI. Each individual acquisition has the potential to generate blockbuster revenues, and each new company is either already in commercial stages or is developing attractive solutions for the $400 billion biotechnology market and the $4 trillion healthcare market.
Biotech companies are known for wild share price swings on drug development news and can see their shares either rocket on good news or crash on bad news. Biotech valuations tend to be substantially higher than most industries because the leverage of one single drug can create several billions of dollars in new wealth. A37 is a broad-spectrum, Immunotherapy drug of great interest because it has the potential to deliver therapeutic solutions for so many cancers and disease conditions. If successful, its value can be enormous. The demonstrated efficacy against breast cancer and the belief it works against a host of cancers and illnesses with minimal adverse side effects has motivated the drug giant, Merck to enter into a clinical trial with Generex.
MRK is conducting a Combination Trial for breast cancer with Generex A37 and their giant blockbuster PD1 Checkpoint Inhibitor Keytruda. As A37 moves forward with MRK, dramatically higher share prices appear to be in Generex future if positive outcomes are published. Generex current market cap of well under $200 million is very small by industry standards and subject to very large overnight revaluations on expected news runway.
Additionally, Generex has the potential to deliver large and fast-growing revenues from the several products and services currently offered and about to be offered. Further increases in Generex share valuations are likely and expected as the company begins enrollment for their combination trial and as the company gets closer to reporting revenues from several profit centers.
August 9, 2019 -- InvestorsHub NewsWire -- via BioResearchAlert
About: Generex Biotechnology Corporation (GNBT)
Share price in strong uptrend for past 10 months.
1 Share dividend for each share owned will only be paid the day after Generex Biotechnology is up-listed to Nasdaq.
Nasdaq Up-listing expected in 30 to 60 days.
Stock dividend will only be paid to float shareholders and not to management or insider shareholders.
Management has completely restructured company into powerful healthcare growth engine.
Generex A37 Immunotherapy Vaccine demonstrates high efficacy with low adverse side effects against breast cancer and believes it’s also effective against many common cancers and diseases.
Combination Phase II trial with MRK Keytruda and GNBT A37 for Breast Cancer enrolling 2019.
Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
Proprietary buccal oral insulin delivery for $27 billion insulin market.
Aggressive acquisition strategy of diagnostics, therapeutics, orthopedic surgical implants and patient care in play with recent closes and signed LOI’s.
Summary
Shares of Generex Biotechnology Corporation (OTC: OTCQB:GNBT) have been rising and continue in a strong uptrend for several reasons. Unlike many biotech companies that are developing just one technology and have only one drug or very few drugs in their pipeline, Generex is successfully executing an aggressive acquisition strategy to own a broad spectrum of diagnostic products, therapeutic products, orthopedic implants, surgical kits, biologic products, and care delivery solutions through their MSO.
Joseph Moscoto, CEO, has thoroughly restructured Generex Biotechnology and has assembled an experienced and effective management team that has successfully architected several acquisitions that have either been closed, or that are under LOI. Each individual acquisition has the potential to generate blockbuster revenues, and each new company is either already in commercial stages or is developing attractive solutions for the $400 billion biotechnology market and the $4 trillion healthcare market.
Biotech companies are known for wild share price swings on drug development news and can see their shares either rocket on good news or crash on bad news. Biotech valuations tend to be substantially higher than most industries because the leverage of one single drug can create several billions of dollars in new wealth. A37 is a broad-spectrum, Immunotherapy drug of great interest because it has the potential to deliver therapeutic solutions for so many cancers and disease conditions. If successful, its value can be enormous. The demonstrated efficacy against breast cancer and the belief it works against a host of cancers and illnesses with minimal adverse side effects has motivated the drug giant, Merck to enter into a clinical trial with Generex.
MRK is conducting a Combination Trial for breast cancer with Generex A37 and their giant blockbuster PD1 Checkpoint Inhibitor Keytruda. As A37 moves forward with MRK, dramatically higher share prices appear to be in Generex future if positive outcomes are published. Generex current market cap of well under $200 million is very small by industry standards and subject to very large overnight revaluations on expected news runway.
Additionally, Generex has the potential to deliver large and fast-growing revenues from the several products and services currently offered and about to be offered. Further increases in Generex share valuations are likely and expected as the company begins enrollment for their combination trial and as the company gets closer to reporting revenues from several profit centers.
3
